Johnson & Johnson (NYSE:JNJ) Shares Acquired by Independent Solutions Wealth Management LLC

Independent Solutions Wealth Management LLC increased its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 0.4% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 21,068 shares of the company’s stock after purchasing an additional 80 shares during the quarter. Independent Solutions Wealth Management LLC’s holdings in Johnson & Johnson were worth $3,414,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Exchange Capital Management Inc. boosted its stake in Johnson & Johnson by 3.9% during the 2nd quarter. Exchange Capital Management Inc. now owns 16,677 shares of the company’s stock worth $2,437,000 after purchasing an additional 625 shares during the period. Busey Bank increased its position in Johnson & Johnson by 1.7% in the 2nd quarter. Busey Bank now owns 263,076 shares of the company’s stock valued at $38,451,000 after acquiring an additional 4,289 shares during the period. Iowa State Bank raised its stake in Johnson & Johnson by 0.4% during the 2nd quarter. Iowa State Bank now owns 47,461 shares of the company’s stock valued at $6,937,000 after acquiring an additional 210 shares during the last quarter. United Bank lifted its position in Johnson & Johnson by 3.3% during the 2nd quarter. United Bank now owns 3,586 shares of the company’s stock worth $524,000 after acquiring an additional 113 shares during the period. Finally, Rockland Trust Co. increased its holdings in shares of Johnson & Johnson by 1.7% in the second quarter. Rockland Trust Co. now owns 118,047 shares of the company’s stock valued at $17,254,000 after purchasing an additional 1,969 shares during the period. 69.55% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the stock. Citigroup reduced their price objective on shares of Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating for the company in a research report on Wednesday, December 11th. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, September 14th. Royal Bank of Canada raised their target price on Johnson & Johnson from $178.00 to $181.00 and gave the company an “outperform” rating in a report on Wednesday, October 16th. Wolfe Research started coverage on shares of Johnson & Johnson in a research note on Friday, November 15th. They set an “outperform” rating and a $190.00 price target on the stock. Finally, Bank of America reaffirmed a “neutral” rating and issued a $166.00 target price on shares of Johnson & Johnson in a report on Tuesday, December 10th. Seven research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Johnson & Johnson has an average rating of “Moderate Buy” and an average target price of $174.73.

Johnson & Johnson Price Performance

Shares of JNJ stock traded down $0.60 during midday trading on Thursday, reaching $144.15. 4,430,231 shares of the company were exchanged, compared to its average volume of 7,140,135. Johnson & Johnson has a 12 month low of $143.13 and a 12 month high of $168.85. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03. The company has a market cap of $347.06 billion, a P/E ratio of 20.86, a PEG ratio of 2.52 and a beta of 0.51. The company’s 50 day moving average price is $155.83 and its two-hundred day moving average price is $156.35.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, October 15th. The company reported $2.42 EPS for the quarter, topping analysts’ consensus estimates of $2.21 by $0.21. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The company had revenue of $22.47 billion for the quarter, compared to the consensus estimate of $22.17 billion. During the same quarter in the previous year, the business earned $2.66 EPS. The company’s quarterly revenue was up 5.2% compared to the same quarter last year. On average, sell-side analysts expect that Johnson & Johnson will post 9.94 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, December 10th. Investors of record on Tuesday, November 26th were issued a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.44%. The ex-dividend date was Tuesday, November 26th. Johnson & Johnson’s payout ratio is 71.78%.

Insider Buying and Selling

In related news, Director Mark A. Weinberger bought 1,000 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, December 12th. The stock was purchased at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the acquisition, the director now owns 1,000 shares in the company, valued at $147,220. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. 0.16% of the stock is currently owned by company insiders.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.